Breaking Update
CollPlant Unveils Ready-to-Print Bioink for Advanced 3D Bioprinting Applications
Israeli company CollPlant has launched BioFlex, an animal-free, ready-to-print bioink for advanced 3D bioprinting in research and drug development.
Jerusalem, 25 February, 2026 (TPS-IL) — CollPlant, an Israeli regenerative medicine company, launched BioFlex, a new product aimed at simplifying and standardizing 3D bioprinting workflows for research and drug development.
BioFlex is a ready-to-print recombinant human collagen bioink system designed for Digital Light Processing 3D bioprinting applications. The animal-free platform enables rapid formulation of bioinks with tunable mechanical properties, supporting the fabrication of advanced tissue models and engineered tissues. Intended for use in both academic laboratories and industrial R&D environments, the system is designed to reduce development timelines while improving reproducibility and tissue-mimetic performance.
